Nurix Therapeutics Inc (NASDAQ:NRIX) saw its stock jump 10% on Wednesday after announcing the start of its pivotal DAYBreak ...

EMA concludes that the primary endpoint and supportive secondary endpoints from prior successful Phase 3 studies conducted in ...

Peter Liese and Katarina Barley are pushing for more relaxed approval regulations for male contraceptives in a letter to the ...

ELA026 has demonstrated promising potential as a frontline treatment for patients with sHLH, a hyperinflammatory disease with high mortality and ...

Advanz Pharma and Alvotech recently announced that the European Medicines Agency accepted a Marketing Authorization Application for AVT23, a proposed biosimilar to Xolair® (omalizumab), aimed at ...

The EU’s new pharmaceutical legislation is one of the most important opportunities ahead, says EMA head Emer Cooke ...

Two European-based biotechs—Indivi of Switzerland and Clouds of Care of Belgium—have inked a collaboration deal with the goal of leveraging precision medicine tools to boost the early phase of ...

The U.S. Food and Drug Administration (FDA) is reviewing Corcept’s application to market relacorilant in the United States to treat patients with platinum-resistant ovarian cancer. The FDA’s ...

Ipsen is acquiring next-gen immuno-oncology biotech ImCheck Therapeutics for its investigational cancer combination therapy ...

Detailed price information for Cellectar Biosciences Inc (CLRB-Q) from The Globe and Mail including charting and trades.